Updates of primary central nervous system lymphoma

Area of Science:

• Neuro-oncology
• Hematology
• Immunology

Background:

• Primary central nervous system lymphoma (PCNSL) is a rare non-Hodgkin lymphoma with poor survival rates.
• Limited understanding of PCNSL pathogenesis and diagnosis has hindered treatment advancements.
• Recent research shows progress in PCNSL diagnosis, pathogenesis, and novel therapeutic strategies.

Purpose of the Study:

• To review recent advancements in the diagnosis, pathogenesis, and treatment of PCNSL.
• To highlight novel biomarkers and therapeutic targets for PCNSL.
• To discuss emerging therapies for relapsed/refractory PCNSL.

Main Methods:

• Review of recent scientific literature on PCNSL.
• Analysis of novel diagnostic biomarkers and their efficiency.
• Evaluation of emerging therapeutic agents and clinical trial data.

Main Results:

• Novel biomarkers show promising diagnostic efficiency for PCNSL.
• PCNSL pathogenesis involves aberrant NF-kappaB signaling, CNVs, and DNA methylation.
• New therapies including BTK inhibitors and CAR T-cell therapy show potential for R/R PCNSL.

Conclusions:

• Significant progress has been made in understanding PCNSL diagnosis and pathogenesis.
• Novel targeted therapies and immunotherapies offer new hope for PCNSL patients, particularly those with R/R disease.
• Continued research and clinical trials are crucial for improving PCNSL outcomes.